Expert guides on PDUFA dates, FDA advisory committees, clinical trials, and AI-driven biotech research.
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
Discover how natural language screening lets biotech investors filter companies using plain English queries, replacing complex spreadsheet-based screening with intuitive AI-powered search.
Understand FDA Orphan Drug Designation, its financial incentives, market exclusivity benefits, and why rare disease biotech companies attract premium valuations.
Learn what to look for in biotech quarterly earnings reports, from cash burn and pipeline updates to guidance changes and hidden signals that move stock prices.
Compare FDA Priority Review and Standard Review timelines, learn what triggers each designation, and understand how review type affects drug approval probability and stock prices.
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Learn how to interpret SEC Form 4 insider trading filings for biotech companies, identify meaningful insider buying patterns, and avoid common misinterpretations.
Understand patent cliffs in biotech and pharma, how loss of exclusivity affects revenue and stock prices, and strategies for investing around patent expiration events.
Learn how to calculate biotech cash runway, identify dilution risk, interpret burn rate trends, and use financial data to time your biotech investments.
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.
Learn what a Complete Response Letter is, why the FDA issues CRLs, how companies respond, and what CRL outcomes mean for biotech stock prices and timelines.
Understand PDUFA dates, how the FDA review process works, and why PDUFA action dates are the most important catalysts in biotech investing.
Learn how FDA Advisory Committee meetings work, how to interpret voting results, and what AdCom outcomes mean for biotech stock prices.
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Learn which SEC filings matter most for biotech companies, what to look for in 10-K, 10-Q, 8-K, and S-1 filings, and how to extract actionable insights.
Explore how artificial intelligence is changing biotech due diligence — from automated data extraction to multi-agent analysis and natural language screening.